RIYADH — The World Well being Group (WHO) introduced that Saudi Arabia, represented within the Saudi Meals and Drug Authority (SFDA), has reached maturity stage 4 (ML4) for medicines and vaccines regulation.
Reaching maturity stage 4, the very best stage of WHO’s classification for regulatory authorities, displays SFDA’s sound and credible necessities aimed toward guaranteeing drug security and bettering common well being.
The Assistant Director-Common for Entry to Medicines and Well being Merchandise on the WHO, Dr. Yukiko Nakatani, stated this achievement by SFDA constitutes a big milestone for the Kingdom and the area.
She added that SFDA is the primary nationwide regulatory authority within the Jap Mediterranean and the third worldwide to attain ML4 primarily based on the benchmarking train of the WHO.
“This achievement additional solidifies the longstanding partnership between the WHO and the Saudi authorities in working in the direction of the targets of complete common well being protection and sustainable growth,” emphasised Nakatani.
Attaining ML4 additionally strengthens the collaborative efforts of each events to make sure and improve entry to high-quality, protected, and efficient medical merchandise. It additionally helps the worldwide market entry of domestically manufactured drugs. — SPA